Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | (FY)Dec 31, 2018 | (FY)Dec 31, 2017 | (FY)Dec 31, 2016 | (FY)Dec 31, 2015 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | ||||||||||
Net income from continuing operations | 219.29%629M | -74.58%197M | 7.53%775M | 124.84%720.7M | -409.34%-2.9B | 4.08%937.9M | -56.24%901.1M | 37.15%2.06B | 20.60%1.5B | 8.13%1.25B |
Deferred tax | 169.80%402M | -61.30%149M | 67.32%385M | 77.96%230.1M | -64.67%129.3M | 13.00%366M | 64.42%323.9M | -49.34%197M | 57.13%388.9M | -17.61%247.5M |
Other non cash items | 26.27%423M | 26.89%335M | 23.25%264M | -2.99%214.2M | -38.15%220.8M | 95.62%357M | 4.35%182.5M | 400.00%174.9M | -338.35%-58.3M | -108.38%-13.3M |
Change In working capital | 171.15%185M | 69.30%-260M | -220.66%-847M | -16.25%702M | 139.28%838.2M | 111.41%350.3M | 131.16%165.7M | -251.49%-531.8M | 7.80%-151.3M | -155.63%-164.1M |
-Change in receivables | -8.96%325M | 154.67%357M | -12.80%-653M | -181.71%-578.9M | 776.05%708.5M | 70.21%-104.8M | -75.02%-351.8M | -2,971.43%-201M | 100.76%7M | -997.26%-921.7M |
-Change in inventory | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 180.41%7.8M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 13.73%1.41B | 76.60%1.24B | -65.45%701M | -1.05%2.03B | 10.81%2.05B | 9.25%1.85B | 20.29%1.69B | -20.62%1.41B | 30.44%1.77B | -20.18%1.36B |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | ||||||||||
Net PPE purchase and sale | 2.33%-168M | 12.24%-172M | 22.99%-196M | -22.89%-254.5M | -25.29%-207.1M | 45.86%-165.3M | -8.69%-305.3M | -14.93%-280.9M | -24.12%-244.4M | -14.48%-196.9M |
Net intangibles purchase and sale | -17.50%-47M | -166.67%-40M | 49.83%-15M | 45.04%-29.9M | 0.73%-54.4M | 9.27%-54.8M | -61.93%-60.4M | -13.03%-37.3M | 8.59%-33M | 1.10%-36.1M |
Net business purchase and sale | 8.21%-246M | -8.06%-268M | 38.90%-248M | -82.92%-405.9M | -37.57%-221.9M | 43.14%-161.3M | 40.59%-283.7M | 33.62%-477.5M | -7.44%-719.3M | -36.88%-669.5M |
Net investment purchase and sale | 546.00%646M | 100.00%100M | -3.66%50M | -83.78%51.9M | -85.05%320M | 156.75%2.14B | 181.72%833.9M | 267.70%296M | --80.5M | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 173.16%278M | 7.09%-380M | 35.93%-409M | -290.70%-638.4M | -109.29%-163.4M | 853.71%1.76B | 136.92%184.5M | 45.46%-499.7M | -1.52%-916.2M | -29.37%-902.5M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | ||||||||||
Net issuance payments of debt | 56.84%-41M | 57.01%-95M | 44.35%-221M | -162.75%-397.1M | 136.94%632.8M | -288.83%-1.71B | -173.48%-440.6M | 2,764.89%599.6M | -104.57%-22.5M | 5.76%492M |
Net common stock issuance | -50.94%-80M | 93.84%-53M | -5.76%-861M | -180.53%-814.1M | -571.76%-290.2M | 79.02%-43.2M | 58.64%-205.9M | -24.39%-497.8M | 28.54%-400.2M | -15.27%-560M |
Cash dividends paid | -0.47%-425M | -15.89%-423M | -15.98%-365M | -157.95%-314.7M | 83.74%-122M | -0.41%-750.5M | 0.55%-747.4M | -21.90%-751.5M | -12.95%-616.5M | -18.65%-545.8M |
Net other financing activities | -390.00%-87M | 135.71%30M | 12.04%-84M | -18.49%-95.5M | -28.55%-80.6M | 42.95%-62.7M | -132.35%-109.9M | 18.87%-47.3M | -147.03%-58.3M | -321.43%-23.6M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -9.40%-989M | 52.69%-904M | 7.10%-1.91B | -721.16%-2.06B | 91.43%-250.5M | -81.06%-2.92B | -105.42%-1.61B | 34.18%-785.6M | -69.53%-1.19B | -23.21%-704M |
Net cash flow | ||||||||||
Beginning cash position | -6.34%1.86B | -43.91%1.99B | -18.36%3.54B | 54.92%4.34B | 27.19%2.8B | 10.16%2.2B | 5.02%2B | -2.26%1.9B | -13.39%1.95B | 19.35%2.25B |
Current changes in cash | 1,615.22%697M | 97.16%-46M | -142.95%-1.62B | -140.72%-666.4M | 137.86%1.64B | 160.15%688.1M | 115.39%264.5M | 136.56%122.8M | -36.21%-335.9M | -156.73%-246.6M |
Effect of exchange rate changes | -12.50%-90M | -225.00%-80M | 149.19%64M | -31.15%-130.1M | -10.59%-99.2M | -45.85%-89.7M | -126.10%-61.5M | -109.32%-27.2M | 636.58%291.9M | 22.62%-54.4M |
End cash Position | 32.63%2.47B | -6.34%1.86B | -43.91%1.99B | -18.36%3.54B | 58.68%4.34B | 24.17%2.73B | 10.16%2.2B | 5.02%2B | -2.26%1.9B | -13.39%1.95B |
Free cash flow | 14.79%1.17B | 114.05%1.02B | -72.52%477M | -2.36%1.74B | 22.07%1.78B | 10.45%1.46B | 21.88%1.32B | -27.33%1.08B | 33.70%1.49B | -25.23%1.11B |
Currency Unit | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | Unqualified Opinion |